Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arketamine
2. D-ketamine
3. (r)-(+)-ketamine
4. (+)-ketamine
5. 33643-49-1
6. Ketamine, R-
7. Ketamine, (r)-
8. Y2ri13h7vw
9. (2r)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
10. Chebi:580604
11. (2r)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
12. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2r)-
13. J238.629a
14. (2r)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone
15. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+)-
16. (s) Ketamine
17. Unii-y2ri13h7vw
18. Arketamine [who-dd]
19. Dsstox_cid_28673
20. Dsstox_rid_82943
21. Dsstox_gsid_48747
22. Schembl16104
23. Chembl467505
24. Gtpl9153
25. Dtxsid2048747
26. Pcn-101
27. Tox21_113205
28. Zinc36294079
29. Ncgc00185909-01
30. Cas-33643-49-1
31. Hr-071603
32. Q20707684
33. (2r)-2-(2-chlorophenyl)-2-methylaminocyclohexan-1-one
34. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (r)-
35. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2r)- (9ci)
36. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+)- (8ci)
37. Rke
| Molecular Weight | 237.72 g/mol |
|---|---|
| Molecular Formula | C13H16ClNO |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | 237.0920418 g/mol |
| Monoisotopic Mass | 237.0920418 g/mol |
| Topological Polar Surface Area | 29.1 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 269 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
(r)-ketamine has known human metabolites that include Norketamine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
API SUPPLIERS
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
PCN-101 (R-ketamine), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: ATAI Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2023
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ATAI Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 (R-ketamine), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 08, 2023
Details:
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor antagonist.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2023
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor a...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 13, 2023
Details:
PCN-101 (R-ketamine), demonstrated an encouraging safety profile and signals of efficacy across all timepoints despite not achieving statistical significance on the primary endpoint.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Otsuka Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2023
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 (R-ketamine), demonstrated an encouraging safety profile and signals of efficacy across all timepoints despite not achieving statistical significance on the primary endpoint.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 06, 2023
Details:
PCN-101 (R-ketamine) is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2022
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 (R-ketamine) is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 17, 2022
Details:
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor antagonist.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 25, 2022
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA rec...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 25, 2022
Details:
PCN-101 is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Precision For Medicine | IQVIA
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2022
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Precision For Medicine | IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PCN-101 is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2022
Details:
In the aggregate, these renewed lock-up agreements represent over 30% of atai’s outstanding common shares and illustrate the confidence of atai’s key shareholders in atai’s platform and its potential to address the growing mental health crisis including its lead asset PCN-101.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Apeiron Investment Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 15, 2021
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Apeiron Investment Group
Deal Size : Undisclosed
Deal Type : Agreement
Details : In the aggregate, these renewed lock-up agreements represent over 30% of atai’s outstanding common shares and illustrate the confidence of atai’s key shareholders in atai’s platform and its potential to address the growing mental health crisis incl...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
December 15, 2021
Details:
Company initiate, Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine), a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as TRD.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2021
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company initiate, Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine), a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as TRD.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 14, 2021
Details:
Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 09, 2021
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 09, 2021
Details:
Under the terms of the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from both companies.
Lead Product(s): R-Ketamine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Otsuka Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Collaboration March 16, 2021
Lead Product(s) : R-Ketamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Perception and Otsuka Enter Collaboration and Licensing Deal for Depression Drug Candidate
Details : Under the terms of the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from bo...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : $20.0 million
March 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
77
PharmaCompass offers a list of R-Ketamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right R-Ketamine manufacturer or R-Ketamine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred R-Ketamine manufacturer or R-Ketamine supplier.
PharmaCompass also assists you with knowing the R-Ketamine API Price utilized in the formulation of products. R-Ketamine API Price is not always fixed or binding as the R-Ketamine Price is obtained through a variety of data sources. The R-Ketamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A R-Ketamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of R-Ketamine, including repackagers and relabelers. The FDA regulates R-Ketamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. R-Ketamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of R-Ketamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A R-Ketamine supplier is an individual or a company that provides R-Ketamine active pharmaceutical ingredient (API) or R-Ketamine finished formulations upon request. The R-Ketamine suppliers may include R-Ketamine API manufacturers, exporters, distributors and traders.
click here to find a list of R-Ketamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
R-Ketamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of R-Ketamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right R-Ketamine GMP manufacturer or R-Ketamine GMP API supplier for your needs.
A R-Ketamine CoA (Certificate of Analysis) is a formal document that attests to R-Ketamine's compliance with R-Ketamine specifications and serves as a tool for batch-level quality control.
R-Ketamine CoA mostly includes findings from lab analyses of a specific batch. For each R-Ketamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
R-Ketamine may be tested according to a variety of international standards, such as European Pharmacopoeia (R-Ketamine EP), R-Ketamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (R-Ketamine USP).
